The 16 Days of Activism Against Gender-Based Violence against women is an international campaign from November 25-December 10. Read more about the campaign's goals and where to access additional resources and support.
The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
An inclusive summit for multidisciplinary experts working with adolescents affected by HIV, which will be held as a series of virtual workshops throughout the month of November. Topics will include youth leadership, mental health and psychosocial support interventions, participatory research approaches, and Mhealth and new technologies, among others.
Some observational data suggest that the progestogen injectable contraceptive depot medroxyprogesterone acetate (DMPA) may increase a woman’s risk of HIV acquisition but a randomized clinical trial did not find a statistically significant incre